|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/22 | (2006.01) |
| A61K 39/395 | (2006.01) | ||
| A61P 19/08 | (2006.01) | ||
| A61K 39/00 | (2006.01) |
| (11) | Number of the document | 3478719 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17823190.8 |
| Date of filing the European patent application | 2017-12-21 | |
| (97) | Date of publication of the European application | 2019-05-08 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-20 |
| (46) | Date of publication of the claims translation | 2021-04-12 |
| (86) | Number | PCT/GB2017/053850 |
| Date | 2017-12-21 |
| (87) | Number | WO 2018/115880 |
| Date | 2018-06-28 |
| (30) | Number | Date | Country code |
| 201662437353 P | 2016-12-21 | US |
| (72) |
JUNKER, Uwe, CH
KNEISSEL, Michaela, CH
HALL, Anthony Kent, NL
EUDY, Rena Joy, US
RIGGS, Matthew Manning, US
|
| (73) |
Mereo Biopharma 3 Limited,
4th Floor 1 Cavendish Place, London W1G 0QF,
GB
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Antisklerostinų antikūnų naudojimas gydant osteogenesis imperfecta |
| USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA |
| Payment date | Validity (years) | Amount | |
| 2025-11-21 | 9 | 208.00 EUR |
| 2026-12-21 |